Market revenue in 2023 | USD 75.4 million |
Market revenue in 2030 | USD 170.4 million |
Growth rate | 12.4% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.08% in 2023. Horizon Databook has segmented the France head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
France’s market is projected to grow at a lucrative rate during the forecast period, owing to the high prevalence of head & neck cancer, well-established healthcare infrastructure, and increased focus on research and development.
According to IARC, in France, the number of new thyroid cancer cases is estimated to increase from 13,109 in 2020 to 13,486 by 2030. Partnerships between companies for R&D initiatives can provide opportunities to expand the head and neck cancer therapeutics market in France.
For instance, in September 2023, Pierre Fabre S.A, a France-based company, partnered with Vernalis Research (a subsidiary of HitGen Inc.) to develop oncology drugs and cancer drug discovery. Similarly, in July 2023, Nanobiotix, a France-based company, licensed an experimental cancer treatment to Johnson & Johnson.
Horizon Databook provides a detailed overview of country-level data and insights on the France head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into France head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account